An ultrasensitive FEN1-aided LCR-electrochemical biosensor enables detection of BCR/ABL1 fusion transcripts in clinical samples for early diagnosis and minimal residual monitoring of CML | Synapse
March 3, 2026
An ultrasensitive FEN1-aided LCR-electrochemical biosensor enables detection of BCR/ABL1 fusion transcripts in clinical samples for early diagnosis and minimal residual monitoring of CML
Key Points
BCR/ABL1 fusion transcripts were detected with an ultrasensitive biosensor, facilitating early diagnosis.
The biosensor achieved high specificity and sensitivity for clinical samples, allowing monitoring of minimal residual disease.
Applications of the electrochemical biosensor include potential widespread implementation for chronic myeloid leukemia patients.
Further validation in diverse clinical settings is essential to ascertain broader implications for CML management.